MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. The company has two marketed products and an advancing pipeline of promising candidates, all designed to treat or prevent a number of debilitating or life-threatening diseases.
Founded in 1988, MedImmune is now the global biologics unit of AstraZeneca plc. MedImmune's state-of-the-art R&D facility and worldwide corporate headquarters is located in Gaithersburg, Maryland with additional facilities located in Pennsylvania, California, Kentucky, the United Kingdom and the Netherlands.
MedImmune’s more than 3,000 employees share a commitment to helping people enjoy longer, healthier and more fulfilling lives. Individual contributions are highly valued in an environment characterized by an open exchange of ideas and information. This entrepreneurial spirit is central to our culture, where a passion for excellence meets cutting-edge technology. As a fully integrated biotechnology company, MedImmune offers employment opportunities spanning all stages of product development and organizational support.
The company's marketed products include Synagis® (palivizumab) and FluMist® (Influenza Virus Vaccine Live, Intranasal), with additional products in clinical testing.
MedImmune, LLC. is an Equal Opportunity Employer and does not discriminate on the basis of race, color, religion, gender, age, national origin, disability, veteran status, or any other characteristic protected by federal, state or local law.